{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:54:01Z","timestamp":1782489241471,"version":"3.54.5"},"reference-count":15,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ICMR-IIRPSG-2024-01-03090"],"award-info":[{"award-number":["ICMR-IIRPSG-2024-01-03090"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Live attenuated vaccines (LAVs) are recommended during moderate corticosteroid therapy (&lt;2\u2009mg\/kg per day) for nephrotic syndrome (NS) largely based on observational\/case\u2013control study data. We aim to conduct a randomised controlled trial (RCT) to assess the safety and immunogenicity of LAVs in children with NS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>To test the safety and immunogenicity of LAVs in NS in children on moderate dose corticosteroid therapy (1.5 mg\/kg alternate day dose with maximum 40 mg alternate day dose; early arm) vs those off corticosteroid therapy for 4 weeks (standard arm), we are conducting a single-centre, open-label, non-inferiority RCT at a tertiary care centre in South India (VACCINES trial: Vaccines in Children on Corticosteroids for NEphrotic Syndrome). Eligible children (after inclusion and exclusion criteria) will be enrolled after obtaining written informed consent (from a legally accepted representative\/parents) as well as assent for children aged &gt;12 years. Two doses of measles, mumps, rubella (MMR) and\/or varicella vaccines will be administered 12 weeks apart, after the initial assessment of seroprotection. Immunological assessment of humoral and cellular immunity will be evaluated in eligible participants. Randomisation into the standard and early arms will be performed during the last 2 weeks of alternate-day therapy (stratified into first episode and relapse patients). Seroconversion assessments will be made at 4, 12, 16 and 52 weeks into the study. The primary objective is to compare the proportion of participants who demonstrate seroconversion after 4 weeks of the first intervention. The secondary outcomes are the antibody geometric mean titres and adverse event profiles including serious events. With a non-inferiority margin of 15% (assuming 86% seroconversion in healthy controls), power of 85% and an alpha error of 5%, 100 patients (including 10% attrition) will be randomised (1:1). Comparisons with 50 healthy children will also be made. The occurrence of three serious adverse events directly attributable to the intervention constitutes a stopping rule. An interim analysis after recruitment of 50% is planned to be presented to an institutional Data Safety Monitoring Board. The first patient was enrolled on 30 June 2025, and enrolment is expected to be completed by February 2028.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has been approved by the Institutional Review Board (IRB) of the Christian Medical College, Vellore (IRB min 2411130, dated 20 November 2024). Results will be published in a peer-reviewed journal and may be presented at medical conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Clinical Trials Registry \u2013 India, CTRI\/2025\/01\/078854 (Jan 16, 2025).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118137","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:31:28Z","timestamp":1778081488000},"page":"e118137","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and immunogenicity of live attenuated vaccines during corticosteroid therapy in children with nephrotic syndrome: protocol for an open-label, non-inferiority, randomised controlled trial (VACCINES trial: VAccines in Children on CorticosteroIds for NEphrotic Syndrome)"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-4296","authenticated-orcid":false,"given":"Georgie","family":"Mathew","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Madhavan","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Sciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev Zachariah","family":"Kompithra","sequence":"additional","affiliation":[{"name":"Department of Child Health, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Kumar","family":"Loganathan","sequence":"additional","affiliation":[{"name":"Department of Child Health, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha Mary","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-040X","authenticated-orcid":false,"given":"Mahesh","family":"Moorthy","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Mammen","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kannangai","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-4138","authenticated-orcid":false,"given":"Prasanna","family":"Samuel","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valsan Philip","family":"Verghese","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Raranveettil","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026062608311933000_16.5.e118137.1","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.619548","article-title":"Pediatric immunization practices in nephrotic syndrome: an assessment of provider and parental knowledge","volume":"8","author":"Tran","year":"2021","journal-title":"Front Pediatr"},{"key":"2026062608311933000_16.5.e118137.2","unstructured":"Table . Recommended timing of live vaccine administration for people receiving corticosteroids | the australian immunisation handbook. 2025. Available: https:\/\/immunisationhandbook.health.gov.au\/resources\/tables\/table-recommended-timing-of-live-vaccine-administration-for-people-receiving-corticosteroids"},{"key":"2026062608311933000_16.5.e118137.3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13312-021-2217-3","article-title":"Steroid sensitive nephrotic syndrome: revised guidelines","volume":"58","author":"Sinha","year":"2021","journal-title":"Indian Pediatr"},{"key":"2026062608311933000_16.5.e118137.4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1542\/peds.78.4.736","article-title":"Clinical overview of varicella vaccine: development and early studies","volume":"78","author":"Takahashi","year":"1986","journal-title":"Pediatrics"},{"key":"2026062608311933000_16.5.e118137.5","doi-asserted-by":"crossref","unstructured":"Kamei K . Live attenuated vaccines in patients receiving immunosuppressive agents. Pediatr Nephrol 2023;1\u201312. doi:10.1007\/s00467-023-05969-z","DOI":"10.1007\/s00467-023-05969-z"},{"key":"2026062608311933000_16.5.e118137.6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01890221"},{"key":"2026062608311933000_16.5.e118137.7","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00467-022-05783-z","article-title":"Is influenza vaccination associated with nephrotic syndrome relapse in children? a multicenter prospective study","volume":"38","author":"Ishimori","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2026062608311933000_16.5.e118137.8","doi-asserted-by":"crossref","unstructured":"Horberg M , Thompson M , Agwu A , et al . Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2024.:ciae479. doi:10.1093\/cid\/ciae479","DOI":"10.1093\/cid\/ciae479"},{"key":"2026062608311933000_16.5.e118137.9","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.37"},{"key":"2026062608311933000_16.5.e118137.10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2017.12.061","article-title":"Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents","volume":"196","author":"Kamei","year":"2018","journal-title":"J Pediatr"},{"key":"2026062608311933000_16.5.e118137.11","doi-asserted-by":"crossref","first-page":"638549","DOI":"10.3389\/fped.2022.638549","article-title":"Comparison of [3H]-thymidine, carboxyfluorescein diacetate succinimidyl ester and Ki-67 in lymphocyte proliferation","volume":"10","author":"Lee","year":"2022","journal-title":"Front Pediatr"},{"key":"2026062608311933000_16.5.e118137.12","doi-asserted-by":"crossref","unstructured":"Ponnachan S , Deepthi B , Dhodapkar R , et al . Seroconversion following varicella vaccination in children and adolescents with nephrotic syndrome. Pediatr Nephrol 2025;181\u20133. doi:10.1007\/s00467-025-07089-2","DOI":"10.1007\/s00467-025-07089-2"},{"key":"2026062608311933000_16.5.e118137.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-001-0789-7"},{"key":"2026062608311933000_16.5.e118137.14","unstructured":"Kesavan TA , Sehgal R , Patel U . IAP standard treatment guidelines. 2022. Available: https:\/\/iapindia.org\/pdf\/Ch-048-febrile-seizures.pdf"},{"key":"2026062608311933000_16.5.e118137.15","first-page":"35","article-title":"Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection","volume":"18","author":"Asano","year":"1975","journal-title":"Biken J"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:39:36Z","timestamp":1782488376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,6]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2026-118137"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118137","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}